ArticleCancers2019
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 68 citations in OpenAlex.
- Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Nature communications · 2026Trial
- Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.Lung · 2026Review
- Beyond tobacco: understanding the growing burden of lung adenocarcinoma in women.Oncology reviews · 2026Review
- Real-world genomic landscape of colon and rectal cancer.FEBS open bio · 2025Article
- Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) ofLung Cancer (Auckland, N.Z.) · 2025Article
- BRAFNPJ precision oncology · 2024Review
- Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.Diagnostics (Basel, Switzerland) · 2024Article
- BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.Journal of cancer research and clinical oncology · 2024Review
- Review
- The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.Nature reviews. Cancer · 2024Review
- Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.NPJ precision oncology · 2023Article
- Oncogenic context shapes the fitness landscape of tumor suppression.Nature communications · 2023Article
- SHP2 participates in decidualization by activating ERK to maintain normal nuclear localization of progesterone receptor.Reproduction (Cambridge, England) · 2023Article
- Non-small-cell lung cancer: how to manageDrugs in context · 2023Review
- Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.EXCLI journal · 2023Review
- [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Review
- Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients HarboringCancers · 2022Article
- Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.Lung cancer (Amsterdam, Netherlands) · 2022Article
- A Complex of Pyrosequencing-Based Methods for Detection of Somatic Mutations in Codons 600 and 601 of theSovremennye tekhnologii v meditsine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.